**ABSTRACT**

An advantageous morphic form of Compound **1** which is also known as CFT7455 and is (S)-3-(6-(4-(morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione and methods to prepare Compound **1** for therapeutic applications are provided. This invention also provides new dosage regimens for administering Compound **1**.

[Figure 19]